Drugs / DR-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01178125 | Aug 2010 → Jan 2013 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DR-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01178125 ↗ |
| Route | Oral | “All subjects will receive 12 months of oral contraceptive therapy with DR-102.” NCT01178125 ↗ |